What Is INR?

INR (international normalized ratio) is a standardized version of the prothrombin time that lets results be compared between labs. It is used mainly to monitor warfarin. The typical range without anticoagulation is 0.8–1.1; the usual target on warfarin for atrial fibrillation or DVT is 2.0–3.0. Critical: above 5.0.

Reading an INR

A higher INR means blood takes longer to clot. Below target means a clot risk; above target means bleeding risk. Check for bleeding signs, interacting drugs and diet changes when the INR moves.

Nursing priorities on warfarin

Check the INR before giving warfarin when one is due, and know the target for the indication. Assess for bleeding: gums, urine, stool, bruising and headache. Teach patients about consistent vitamin K intake and interacting drugs. Labs Drills includes coagulation cases where you decide whether to give, hold or report.

PT and INR together

The prothrombin time is reported in seconds and differs between labs because reagents differ. The INR adjusts for this so a result means the same anywhere. That is why warfarin targets are written as INR, not PT.

Worked example

A patient on warfarin for atrial fibrillation has an INR of 4.1 with no bleeding.

  1. Target 2.0–3.0: 4.1 is above
  2. Critical cut-off in Labs Drills: above 5.0: not reached

Answer: Supratherapeutic INR: hold per order, assess for bleeding and notify the prescriber per policy.

Common mistakes

Frequently asked questions

What is a normal INR?

About 0.8–1.1 without anticoagulants.

What is the INR target on warfarin?

Usually 2.0–3.0 for atrial fibrillation or DVT; some indications differ.

What does a high INR mean?

Blood clots more slowly, so bleeding risk rises.

Is INR the same as PT?

INR is calculated from the PT so results are comparable across labs.

Learn and practice

References

  1. MedlinePlus: Prothrombin time (PT/INR), https://medlineplus.gov/lab-tests/prothrombin-time-test-and-inr-ptinr/
  2. Holbrook A et al. Evidence-Based Management of Anticoagulant Therapy (CHEST 2012). Chest 2012;141(2 Suppl):e152S–e184S, https://doi.org/10.1378/chest.11-2295
  3. Kearon C et al. Antithrombotic Therapy for VTE Disease (CHEST 2012). Chest 2012;141(2 Suppl):e419S–e496S, https://doi.org/10.1378/chest.11-2301
  4. Cleveland Clinic Laboratories: Critical and urgent values, https://clevelandcliniclabs.com/laboratory-resources/policies-procedures/critical-and-urgent-values-results/

Educational practice only. This page supports exam practice and is not a clinical decision tool. Ranges and protocols vary; follow your facility's reference ranges, policies and current product information.